Advice

in the absence of a submission from the holder of the marketing authorisation:

ceftolozane/tazobactam (Zerbaxa®) is not recommended for use within NHSScotland.

Indication under review: In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice357KB (PDF)

Download

Medicine details

Medicine name:
ceftolozane/tazobactam (Zerbaxa)
SMC ID:
SMC2256
Indication:

In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.

Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Respiratory system
Submission type
Non submission
Status
Not recommended
Date advice published:
09 December 2019